The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Open accessAbstract
There are no disease-modifying treatments for adult human neurodegenerative diseases. Here we test RNA-targeted therapies in two mouse models of spinocerebellar ataxia type 2 (SCA2), an autosomal dominant polyglutamine disease. Both models recreate the progressive adult-onset dysfunction and degeneration of a neuronal network that are seen in patients, including decreased firing frequency of cerebellar Purkinje cells and a decline in motor function. We developed a potential therapy directed at the ATXN2 gene by screening 152 antisense oligonucleotides (ASOs). The most promising oligonucleotide, ASO7, downregulated ATXN2 mRNA and protein, which resulted in delayed onset of the SCA2 phenotype. After delivery by intracerebroventricular injection to ATXN2-Q127 mice, ASO7 localized to Purkinje cells, reduced cerebellar ATXN2 expression below 75% for more than 10 weeks without microglial activation, and reduced the levels of cerebellar ATXN2. Treatment of symptomatic mice with ASO7 improved motor function compared to saline-treated mice. ASO7 had a similar effect in the BAC-Q72 SCA2 mouse model, and in both mouse models it normalized protein levels of several SCA2-related proteins expressed in Purkinje cells, including Rgs8, Pcp2, Pcp4, Homer3, Cep76 and Fam107b. Notably, the firing frequency of Purkinje cells returned to normal even when treatment was initiated more than 12 weeks after the onset of the motor phenotype in BAC-Q72 mice. These findings support ASOs as a promising approach for treating some human neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Due to the precision afforded by complementary binding of an ASO to its target transcript of interest, ASOs have emerged as an invaluable tool in specifically altering levels and/or processing of a variety of proteins involved in neurodegenerative diseases, most of which have been the disease-causing protein itself (38, 51–54).”
From Reduction of nemo-like kinase increases lysosome biogenesis and ameliorates TDP-43–related neurodegeneration (2023) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
Xia, H., Mao, Q.-W., Eliason, S., Harper, S., Martins, I. H., Orr, H., Paulson, H., Yang, L., Kotin, R., & Davidson, B. (2004) · Nature Medicine · doi:10.1038/nm1076 · Cited by 689
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationTherapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice
Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., Messing, J., Kim, H. J., Soriano, A., Auburger, G., et al. (2017) · Nature · doi:10.1038/nature22038 · Cited by 571
Self-citationSwayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 483
Self-citationThe genetics and neuropathology of Parkinson’s disease
Houlden, H., & Singleton, A. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1013-5 · Cited by 331
Huynh, D. P., Figueroa, K. P., Hoang, N., & Pulst, S.-M. (2000) · Nature Genetics · doi:10.1038/79162 · Cited by 330
Self-citationDeranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 2
Liu, J., Tang, T.-S., Tu, H., Nelson, O. L., Herndon, E., Huynh, D. P., Pulst, S. M., & Борисович, Б. И. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0660-09.2009 · Cited by 299
Self-citationCarroll, J. B., Warby, S. C., Southwell, A. L., Doty, C. N., Greenlee, S., Skotte, N. H., Hung, G., Bennett, C. F., Freier, S. M., & Hayden, M. R. (2011) · Molecular Therapy · doi:10.1038/mt.2011.201 · Cited by 293
Self-citationHansen, S. T., Meera, P., Otis, T. S., & Pulst, S. M. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds427 · Cited by 173
Self-citation
Cited by
Sorted by citations
Items 201–300 of 318
Small Interfering RNAs and RNA Therapeutics in Cardiovascular Diseases
Bansal, P., & Arora, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1671-9_23 · Cited by 9
Sundberg, C. A., Lakk, M., Paul, S., Figueroa, K. P., Scoles, D. R., Pulst, S. M., & Križaj, D. (2021) · The Journal of Comparative Neurology · doi:10.1002/cne.25228 · Cited by 9
Self-citationNovel Therapeutic Challenges in Cerebellar Diseases
Matilla‐Dueñas, A., Infante, J., Serrano, C., Ivánovic-Barbeito, Y., Álvarez, R., & Sánchez, I. (2012) · Springer eBooks · doi:10.1007/978-3-030-23810-0_106 · Cited by 9
Lipid Dyshomeostasis and Inherited Cerebellar Ataxia
Zhao, J., Zhang, H., Fan, X., Yu, X., & Huai, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02826-2 · Cited by 9
Goto, A., Yamamoto, S., Igari, T., Matsumoto, S.-I., Chisaki, I., Iida, K., Nakayama, M., Oda, A., Kakoi, Y., Uchida, A., et al. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001331 · Cited by 8
Epigenetic editing for autosomal dominant neurological disorders
Waldo, J. J., Halmai, J. A. N. M., & Fink, K. D. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1304110 · Cited by 8
Cytoplasmic RNA granules, ribostasis, and neurodegeneration
Benarroch, E. E. (2018) · Neurology · doi:10.1212/wnl.0000000000005172 · Cited by 8
Repeat-associated non-AUG translation as a common mechanism for the polyGln ataxias
Báñez-Coronel, M., Zu, T., Aldridge, M., Guo, S., Ajredini, R., Morrison, D., Tays, A. B., Duvick, L. A., Pletniková, O., Yachnis, A. T., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116741 · Cited by 7
Ma, T., Feng, L., Wei, S., Wang, Y., Li, G., Lu, Y., Zhang, Y., Chu, Y., Wang, W., & Zhang, H. (2023) · Brain and Behavior · doi:10.1002/brb3.3013 · Cited by 7
Two–for–one on potential therapies
Zhang, K., & Rothstein, J. D. (2017) · Nature · doi:10.1038/nature21911 · Cited by 8
Antisense-Therapie neurologischer Erkrankungen
Pulst, S. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0724-4 · Cited by 9
Self-citationHuelsmeier, J., Walker, E., Bakthavachalu, B., & Ramaswami, M. (2021) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkab355 · Cited by 10
Shi, X., Xu, Y., Wang, B., Li, Z., Yu, S., Dong, H., Zhao, W., Jiang, D., Chen, H., & Xu, J. (2023) · Angewandte Chemie · doi:10.1002/ange.202302930 · Cited by 7
Chen, C., Fang, X., & Sun, S.-C. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9043 · Cited by 7
Advances in cerebellar disorders: pre-clinical models, therapeutic targets, and challenges
Manto, M. U., Cendelín, J., Strupp, M., & Mitoma, H. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2263911 · Cited by 8
ATXN7-Related Cone-Rod Dystrophy
Nassisi, M., Coarelli, G., Blanchard, B., Dubec‐Fleury, C., Drine, K., Kitic, N., Sancho, S., Hilab, R., du Montcel, S. T., Junge, C., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.0001 · Cited by 6
Human stem cell models of polyglutamine diseases: Sources for disease models and cell therapy
He, L., Zhao, C. N., Peng, L., Tang, B., & Jiang, H. F. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113573 · Cited by 6
Can we improve slow learning in cerebellar patients?Preprint
Hulst, T., Mamlins, A., Frens, M. A., Chang, D., Goericke, S. L., Timmann, D., & Donchin, O. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.03.185959 · Cited by 6
Thakur, P., Lackinger, M., Diamantopoulou, A., Rao, S. B., Chen, Y., Khalizova, K., Ferng, A., Mazur, C., Kordasiewicz, H. B., Shprintzen, R. J., et al. (2024) · eLife · doi:10.7554/elife.103328 · Cited by 6
Multiomics approach identifies SERPINB1 as candidate biomarker for spinocerebellar ataxia type 2
Almaguer-Mederos, L. E., Key, J., Şen, N.-E., Canet-Pons, J., Döring, C., Meierhofer, D., Gispert-Sánchez, S., Cuello‐Almarales, D., Almaguer‐Gotay, D., Osorio-González, L. M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-29070-7 · Cited by 5
Cerebellar Micro-RNA Profile in a Mouse Model of Spinocerebellar Ataxia Type 2
Paul, S., Dansithong, W., Gandelman, M., Figueroa, K. P., Scoles, D. R., & Pulst, S. M. (2024) · Neurology Genetics · doi:10.1212/nxg.0000000000200144 · Cited by 6
Self-citationPulst, S. M. (2006) · Neurology Genetics · doi:10.1007/978-3-030-75817-2_25 · Cited by 5
Self-citationTaghavi, A., & Yildirim, I. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.830161 · Cited by 5
Gene Suppression Therapies in Hereditary Cerebellar Ataxias: A Systematic Review of Animal Studies
dos Santos, C. M., Malheiro, S. F., Correia, M. A., & Damásio, J. (2023) · Cells · doi:10.3390/cells12071037 · Cited by 6
Staufen blocks autophagy in neurodegenerationPreprint
Paul, S., Dansithong, W., Gandelman, M., Figueroa, K. P., Zu, T., Ranum, L. P. W., Scoles, D. R., & Pulst, S. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/659649 · Cited by 5
Self-citationNguyen, J., Lachgar-Ruiz, M., Higginbotham, E. J., Coleman, M., Coleman, J., Shao, W., Scotchman, E., Pritchard, A. J., Bell, K. M., Chitty, L. S., et al. (2026) · Neurology · doi:10.1212/wnl.0000000000214645 · Cited by 4
Site-Specific Radioiodination of Oligonucleotides with a Phenolic Element in a Programmable Approach
Zhao, H., Qin, Y., Liu, D., Geng, X., Wang, C., Ding, D., Ding, X., Xia, Q., Liu, J., Wang, R., et al. (2022) · Molecules · doi:10.3390/molecules27196257 · Cited by 4
Ataxin 2 reduction rescues motor defects
Crunkhorn, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.104 · Cited by 3
RNA in the spotlight: the dawn of RNA therapeutics in the treatment of human disease
Stellos, K. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx170 · Cited by 4
Mystery of Expansion: DNA Metabolism and Unstable Repeats
Grishchenko, I. V., Purvinsh, Y. V., & Yudkin, D. V. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41283-8_7 · Cited by 5
Diffusion magnetic resonance imaging-based surrogate marker in amyotrophic lateral sclerosis
Saito, Y. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00047 · Cited by 4
RetractedCastelli, L. M., Vasta, R., Allen, S. P., Waller, R., Chiò, A., Traynor, B. J., & Kirby, J. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.02.001 · Cited by 4
Ataxina-2, nuevo blanco en enfermedades genéticas complejas
Ramirez-Garcia, S. A., Sánchez‐Corona, J., Ortega-Pacheco, D., Ramírez-Bohórquez, E., & García‐Cruz, D. (2018) · Gaceta Médica de México · doi:10.24875/gmm.18003473 · Cited by 4
Targeting Staufen 1 with antisense oligonucleotides for treating ALS and SCA2Preprint
Scoles, D. R., Paul, S., Dansithong, W., Figueroa, K. P., Gandelman, M., Royzen, F., Anderson, C. J., & Pulst, S. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.16.516816 · Cited by 4
Self-citationTreatment of primary adult-onset neurodegenerative cerebellar ataxias
Ariello, L. E., Rastall, D. P. W., & Rosenthal, L. S. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00805 · Cited by 4
Animal Models of FUS-Proteinopathy: A Systematic Review
Rezvykh, A. P., Shteinberg, D. A., Bronovitsky, E. V., Ustyugov, A. A., & Funikov, S. Y. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924140037 · Cited by 3
Jiang, J., Zhang, M., Xia, W., Ding, C., Li, J., Hu, X., Lu, J., Li, H., Meng, Q., Cheung, H., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01176-0 · Cited by 3
Almaguer-Mederos, L. E., Kandi, A. R., Şen, N.-E., Canet-Pons, J., Berger, L.-M., Stokes, M. P., Abell, K., Key, J., Gispert, S., & Auburger, G. W. J. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101072 · Cited by 5
Antisense Oligonucleotide Therapy for Spinocerebellar Ataxias: Good News for Terrible Diseases
Teive, H. A. G., Camargo, C. H. F., & Munhoz, R. P. (2018) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12627 · Cited by 3
Matsubayashi, T., Yoshioka, K., Mon, S. S. L., Katsuyama, M., Jia, C., Yamaguchi, T., Kuwahara, H., Nagata, T., Nakagawa, O., Obika, S., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102161 · Cited by 3
Chen, Y., Tian, H., Zhu, Q., Zhang, R., Liang, D., Wang, J.-Q., Feng, R., Qin, C., Ma, M., Jiang, H. F., et al. (2024) · Movement Disorders · doi:10.1002/mds.30050 · Cited by 3
Thakur, P., Lackinger, M., Diamantopoulou, A., Rao, S. B., Chen, Y., Khalizova, K., Ferng, A., Mazur, C., Kordasiewicz, H. B., Shprintzen, R. J., et al. (2024) · eLife · doi:10.7554/elife.103328.3 · Cited by 9
Targeted delivery of nucleic acids using microfluidic systems
Hosseini, M., Rabiee, N., & Bagherzadeh, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818791-3.00009-7 · Cited by 3
Shorrock, H. K., Aliyeva, A., Frias, J. A., DeMeo, V. A., Lennon, C. D., DeMeo, C. C., Mascorro, A. K., Shaughnessy, S., Mazdiyasni, H., Cleary, J. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.17.608349 · Cited by 3
Almaguer-Mederos, L. E., Kandi, A. R., Şen, N.-E., Canet-Pons, J., Berger, L.-M., Key, J., Brunstein, M. E., Münch, C., Gispert, S., & Auburger, G. W. J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.06.622233 · Cited by 3
Şen, N.-E., von Bernhardi, J. E., Adeyemi, J. O., Arsović, A., Canet-Pons, J., Miralles, A. J., Key, J., Bina, L., Romano, V., Fellenz, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.08.669189 · Cited by 3
Maternal microbiome-derived propionate regulates offspring myelination via histone lactylation
Zhang, Y., Han, B., Wang, X., Li, Y., Zou, Y.-R., Li, S.-H., Li, X., Li, Y.-B., Huang, Y., Sun, D.-Z., et al. (2026) · Brain · doi:10.1093/brain/awag034 · Cited by 2
Management of spinocerebellar ataxia
Vinokurov, E. K., Marinina, K. S., & Борисович, Б. И. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2665356 · Cited by 2
Quantification of Solid Embryonic Cerebellar Graft Volume in a Degenerative Ataxia Model
Purkartová, Z., Krakorová, K., Babuška, V., Tůma, J., Houdek, Z., Choudhury, N. R., Kapl, S., Kolinko, Y., Sucha, M., Porras‐García, E., et al. (2024) · The Cerebellum · doi:10.1007/s12311-024-01676-z · Cited by 2
Deciphering the interactome of Ataxin-2 and TDP-43 in iPSC-derived neurons for potential ALS targets
Tian, Y., Heinsinger, N. M., Hu, Y., Lim, U.-M., Wang, Y., Fernandis, A. Z., Parmentier‐Batteur, S., Klein, B., Uslaner, J. M., & Smith, S. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308428 · Cited by 3
Waerling, R. D., Blechingberg, J., Kayser, J. D., Lindquist, S. G., Vinther‐Jensen, T., Nielsen, J. E., & Dunø, M. (2025) · The Cerebellum · doi:10.1007/s12311-025-01815-0 · Cited by 2
Distinct patterns of cerebral and spinal pathology along the spectrum of ATXN2-related disorders
Wolmer, P. S., de Borba, F. C., de Rezende, T. J. R., González‐Salazar, C., Pedroso, J. L., Barsottini, O. G. P., Kleinerová, J., Bede, P., Marques, W., & França, M. C. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13037-9 · Cited by 2
Dietary and lifestyle interventions for the management of hereditary ataxias
Yang, W., Thompson, B., & Kwa, F. A. A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1548821 · Cited by 2
Role of Neuroinflammation in Neurodegenerative Disorders
Mohan, V., Edamakanti, C. R., & Sharma, V. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821974-4.00001-7 · Cited by 2
Chen, G., Peng, Z., Zhong, Y., Lian, X., Li, Y., Zhai, Z., Ju, J., & Chen, J. (2022) · Journal of Neurorestoratology · doi:10.26599/jnr.2022.9040002 · Cited by 2
Han, C., Wang, Q., Liu, C., Li, Z., Du, T., Sui, Y., Zhang, X., Zhang, J., Xiao, Y., Cai, G., et al. (2022) · Brain Sciences · doi:10.3390/brainsci12091206 · Cited by 2
Klockgether, T. (2023) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2015-3305 · Cited by 2
Chen, Z., Hicks, A. R., Brenton, J., Grant‐Peters, M., Reynolds, R. H., Gustavsson, E. K., Rocca, C., Perez, G. R., Garza, R., García-Ruiz, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.03.631007 · Cited by 2
Gene therapy in neurodegenerative disorders
Ali, H. T., Sula, I., Elrefaey, A., Ashour, Y., Eltaras, M. M., Mohamed, H., & Meshref, M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00036-1 · Cited by 1
Targeting c-Myc with antisense oligonucleotides to induce apoptosis in tumor cells
Ye, Y., Wang, Y., Zong, Z., & Chen, S. (2025) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2025.2542835 · Cited by 1
Molecular Pathways and Recent Therapeutic Strategies for Polyglutamine Diseases
Roy, S. K., Barman, A., Richard, S. A., & Lacmane, B. A. (2025) · Current Molecular Medicine · doi:10.2174/0115665240393446250829084646 · Cited by 1
Smith, V. L., Gidi, B. Z., Bragg, R. M., Cantle, J. P., Ben-Varon, A., Noble, B., Prades, S., Compton, A., Greenfield, J., Korecka, J. A., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102815 · Cited by 2
A review on RNA technologies renaissance: a paradigm shift shaping the future of modern medicine
Singh, S. P., Mundlia, P., Sharma, A. M., Kaur, H., Chaubey, B., Khajuria, A., Chatterjee, M., Jaiswal, P. K., Ranawat, P., Singh, G., et al. (2026) · Next Bioengineering · doi:10.1016/j.nxbio.2026.100016 · Cited by 1
Park, S. M., Kim, S. S., Cho, E., Lee, G. B., Lee, J. H., Kim, D. W., Kim, J.-E., Kim, J.-E., Choi, G. E., Lee, H.-W., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03811-5 · Cited by 1
Development of Physiological Activity in the Cerebellum
Jayabal, S., & Watt, A. J. (2019) · Springer eBooks · doi:10.1007/978-3-319-97911-3_111-1 · Cited by 1
New Approaches in Studies of the Molecular Pathogenesis of Type 2 Spinocerebellar Ataxia
Egorova, P. A., & Борисович, Б. И. (2020) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-020-00988-x · Cited by 1
Development of Physiological Activity in the Cerebellum
Jayabal, S., & Watt, A. J. (2019) · Springer eBooks · doi:10.1007/978-3-319-97911-3_111-2 · Cited by 1
Modeling amyotrophic lateral sclerosis through Ataxin-2 pathology
Şen, N.-E., & Auburger, G. W. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89833-1.00013-6 · Cited by 1
Autosomal and X-Linked Degenerative Ataxias: From Genetics to Promising Therapeutics
Hadji, A., Louit, A., Roy, V., Blais, M., Berthod, F., Gros‐Louis, F., & Dupré, N. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-24345-5_5 · Cited by 1
Leveraging human–mouse studies to advance the genetics of hearing impairment in Africa
James, K., & Oluwole, O. G. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3714 · Cited by 1
Sahay, S., Wen, J., Scoles, D. R., Simeonov, A. M., Dexheimer, T. S., Jadhav, A., Kales, S. C., Sun, H., Pulst, S. M., Facelli, J. C., et al. (2025) · Biology · doi:10.3390/biology14050522 · Cited by 1
Self-citationNeural mechanism and therapeutic strategy of cerebellar ataxia
Xie, S.-T., Li, H., Song, B. K., Zhang, X., Jian-Jun, W. A. N. G., & Zhu, J. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0148 · Cited by 1
Huelsmeier, J., Walker, E., Bakthavachalu, B., & Ramaswami, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.01.462783 · Cited by 1
Thakur, P., Lackinger, M., Diamantopoulou, A., Rao, S. B., Chen, Y., Khalizova, K., Ferng, A., Mazur, C., Kordasiewicz, H. B., Shprintzen, R. J., et al. (2025) · eLife · doi:10.7554/elife.103328.2 · Cited by 1
Robinson, R. (2017) · Neurology Today · doi:10.1097/01.nt.0000520468.79029.14
Latest Innovations in Life Sciences
Sanadhya, D., Roy, B., Malik, C., & Sharma, S. (2017) · LS International Journal of Life Sciences · doi:10.5958/2319-1198.2017.00018.5
Progression of spinocerebellar ataxia type 2. What do we need to know?
Ferraz, H. B. (2017) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20170166
Halbach, M. V., Şen, N.-E., Canet-Pons, J., Kuppens, B. W., Segers, M., Schonewille, M., Rollmann, E., Seidel, K., Rüb, U., Meierhofer, D., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/333443
These violent repeats have violent extends
Couthouis, J., & Gitler, A. D. (2018) · Neurology Genetics · doi:10.1212/nxg.0000000000000247
Bechek, S. C., & Gitler, A. D. (2018) · Brain · doi:10.1093/brain/awy294
Changes in protein function underlies the disease spectrum in patients with CHIP mutationsPreprint
Madrigal, S. C., McNeil, Z., Sanchez-Hodge, R., Shi, C.-H., Patterson, C., Scaglione, K. M., & Schisler, J. C. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/620591
Ataxin-2, a new target in complex genetic diseases
Ramirez-Garcia, S. A., Sánchez‐Corona, J., Ortega-Pacheco, D., Ramírez-Bohórquez, E., & García‐Cruz, D. (2019) · Gaceta Médica de México · doi:10.24875/gmm.m19000232
How does editing the genome improve targeting DNA and RNA for cerebellar ataxias?
Gandini, J., & Manto, M. U. (2020) · Future Neurology · doi:10.2217/fnl-2019-0019
Filling a Knowledge Gap: Prevalence of Ataxia and Spastic Paraplegia in Eastern Quebec
Slow, E. (2021) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2021.15
RNA-Mediated Metabolic Defects in Microsatellite Expansion Diseases
Zhang, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-76571-2_8
Small molecule v-ATPase inhibitor Etidronate lowers levels of ALS protein ataxin-2Preprint
Kım, G., Nakayama, L., Blum, J. A., Akiyama, T., Boeynaems, S., Chakraborty, M., Couthouis, J., Tassoni-Tsuchida, E., Rodriguez, C. M., Bassik, M. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.20.473567
Development of Physiological Activity in the Cerebellum
Jayabal, S., & Watt, A. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-23810-0_111
Dürr, A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734287980.793552229
Dürr, A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733458894.793552253
Disney, M. D. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736176320.793563807
(2017) · Nature Biotechnology · doi:10.1038/nbt.3872
He, L., Wang, S., Zhao, H., Li, S., Han, X. B., Chen, Z., Wang, C., Peng, Y., Peng, H., Peng, L., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-88222/v1
Gandini, J., & Manto, M. U. (2023) · Springer eBooks · doi:10.1007/978-3-031-15070-8_108
Blood and CSF Biomarkers in Autosomal Dominant Cerebellar Ataxias
Coarelli, G., & Dürr, A. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-24345-5_13
ASOs Against ATXN2 in Preclinical and Phase 1 Trials
Pulst, S. M. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-24345-5_15
Self-citationSpinocerebellar Ataxia Type 7: From Mechanistic Pathways to Therapeutic Opportunities
Switonski, P. M., & Spada, A. R. L. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-24345-5_17
Novel Discovery Reveals Cause of Genetic Mutation in Rare Type of Spinocerebellar Ataxia
Talan, J. (2024) · Neurology Today · doi:10.1097/01.nt.0001024556.17349.d7
Thakur, P., Lackinger, M., Diamantopoulou, A., Rao, S. B., Chen, Y., Khalizova, K., Ferng, A., Mazur, C., Kordasiewicz, H. B., Shprintzen, R. J., et al. (2024) · eLife · doi:10.7554/elife.103328.1
Almaguer-Mederos, L. E., Key, J., Sen, N., Canet-Pons, J., Döring, C., Meierhofer, D., Gispert-Sánchez, S., Cuello‐Almarales, D., Almaguer‐Gotay, D., González, L. M. O., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.18.649103
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21884-2.00033-7
Metadata
- Authors
- Scoles, D. R., Meera, P., Schneider, M. D., Paul, S., Dansithong, W., Figueroa, K. P., Hung, G., Rigo, F., Bennett, C. F., Otis, T. S., & Pulst, S. M.
- Affiliations
- University of Utah (US)
- University of California, Los Angeles (US)
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Scoles, Daniel R.
- Pulst, Stefan M.
- ORCID
- Venue
- Nature
- Published
- 2017-04-12
- Volume
- 544
- Issue
- 7650
- Pages
- 362-366
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6625650
- OpenAlex
- W2606911774
- Cited by
- 319
- References
- 31
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 26 · 2023: 28 · 2022: 39 · 2021: 37 · 2020: 37 · 2019: 43 · 2018: 45 · 2017: 21
- FWCI
- 19.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Target ALS
- National Institute of Neurological Disorders and Stroke (U01NS103883, R01NS033123, R01NS090930, R21NS081182, RC4NS073009, R56NS033123, R01NS097903, R37NS033123, R21NS103009)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- spinocerebellar ataxia type 2, antisense oligonucleotides, ATXN2, polyglutamine expansion, Purkinje cells, TDP-43 aggregation, amyotrophic lateral sclerosis, RNA-targeted therapeutics, neurodegeneration, mouse model, motor function, lifespan
- MeSH terms
- Ataxin-2, Action Potentials, Animals, Disease Models, Animal, Female, Gene Expression Regulation, Humans, Male, Mice, Transgenic, Movement, Phenotype, Purkinje Cells, RNA, Messenger, Oligonucleotides, Antisense, Spinocerebellar Ataxias, Rotarod Performance Test, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
